OBJECTIVE: To describe inter-center hospital variation in inhaled nitric oxide (iNO) administration to infants born prior to 34 weeks' gestation at US children's hospitals. METHODS: This was a retrospective cohort study using the Pediatric Health Information System to determine the frequency, age at first administration, and length of iNO use among 22 699 consecutive first admissions of unique <34 weeks' gestation infants admitted to 37 children's hospitals from January 1, 2007, through December 31, 2010. RESULTS: A total of 1644 (7.2%) infants received iNO during their hospitalization, with substantial variation in iNO use between hospitals (range across hospitals: 0.5%-26.2%; P < .001). The age at which iNO was started varied by hospital (mean: 20.0 days; range: 6.0-65.1 days, P < .001), as did the duration of therapy (mean: 13.1 days; range: 1.0-31.1 days; P < .001). Preterm infants who received iNO were less likely to survive (36.3% mortality vs 8.3%; odds ratio: 6.27; P < .001). The association between the use of iNO and mortality persists in propensity score-adjusted analyses controlling for demographic factors and diagnoses associated with the use of iNO (odds ratio: 3.79; P < .0001). CONCLUSIONS: iNO practice patterns in preterm infants varied widely among institutions. Infants who received iNO were less likely to survive, suggesting that iNO is used in infants already at high risk of death. Adherence to National Institutes of Health consensus guidelines may decrease variation in iNO use.
RCT Entities:
OBJECTIVE: To describe inter-center hospital variation in inhaled nitric oxide (iNO) administration to infants born prior to 34 weeks' gestation at US children's hospitals. METHODS: This was a retrospective cohort study using the Pediatric Health Information System to determine the frequency, age at first administration, and length of iNO use among 22 699 consecutive first admissions of unique <34 weeks' gestation infants admitted to 37 children's hospitals from January 1, 2007, through December 31, 2010. RESULTS: A total of 1644 (7.2%) infants received iNO during their hospitalization, with substantial variation in iNO use between hospitals (range across hospitals: 0.5%-26.2%; P < .001). The age at which iNO was started varied by hospital (mean: 20.0 days; range: 6.0-65.1 days, P < .001), as did the duration of therapy (mean: 13.1 days; range: 1.0-31.1 days; P < .001). Preterm infants who received iNO were less likely to survive (36.3% mortality vs 8.3%; odds ratio: 6.27; P < .001). The association between the use of iNO and mortality persists in propensity score-adjusted analyses controlling for demographic factors and diagnoses associated with the use of iNO (odds ratio: 3.79; P < .0001). CONCLUSIONS:iNO practice patterns in preterm infants varied widely among institutions. Infants who received iNO were less likely to survive, suggesting that iNO is used in infants already at high risk of death. Adherence to National Institutes of Health consensus guidelines may decrease variation in iNO use.
Authors: Roberta A Ballard; William E Truog; Avital Cnaan; Richard J Martin; Philip L Ballard; Jeffrey D Merrill; Michele C Walsh; David J Durand; Dennis E Mayock; Eric C Eichenwald; Donald R Null; Mark L Hudak; Asha R Puri; Sergio G Golombek; Sherry E Courtney; Dan L Stewart; Stephen E Welty; Roderic H Phibbs; Anna Maria Hibbs; Xianqun Luan; Sandra R Wadlinger; Jeanette M Asselin; Christine E Coburn Journal: N Engl J Med Date: 2006-07-27 Impact factor: 91.245
Authors: Krisa P Van Meurs; Linda L Wright; Richard A Ehrenkranz; James A Lemons; M Bethany Ball; W Kenneth Poole; Rebecca Perritt; Rosemary D Higgins; William Oh; Mark L Hudak; Abbot R Laptook; Seetha Shankaran; Neil N Finer; Waldemar A Carlo; Kathleen A Kennedy; Jon H Fridriksson; Robin H Steinhorn; Gregory M Sokol; G Ganesh Konduri; Judy L Aschner; Barbara J Stoll; Carl T D'Angio; David K Stevenson Journal: N Engl J Med Date: 2005-07-07 Impact factor: 91.245
Authors: Heather C Kaplan; Meredith E Tabangin; Diana McClendon; Jareen Meinzen-Derr; Peter A Margolis; Edward F Donovan Journal: Pediatrics Date: 2010-07-05 Impact factor: 7.124
Authors: Ciaran S Phibbs; Laurence C Baker; Aaron B Caughey; Beate Danielsen; Susan K Schmitt; Roderic H Phibbs Journal: N Engl J Med Date: 2007-05-24 Impact factor: 91.245
Authors: Michael D Schreiber; Karen Gin-Mestan; Jeremy D Marks; Dezheng Huo; Grace Lee; Pimol Srisuparp Journal: N Engl J Med Date: 2003-11-27 Impact factor: 91.245
Authors: Naomi S Bardach; Tumaini R Coker; Bonnie T Zima; J Michael Murphy; Penelope Knapp; Laura P Richardson; Glenace Edwall; Rita Mangione-Smith Journal: Pediatrics Date: 2014-03-17 Impact factor: 7.124
Authors: Walid A Hussain; Deborah S Bondi; Pooja Shah; Sherwin E Morgan; Sudhir Sriram; Michael D Schreiber Journal: J Pediatr Pharmacol Ther Date: 2022-03-21
Authors: Q Jiang; X Gao; C Liu; D Chen; X Lin; S Xia; D Zhuang; C Yang; W Zhu; L Liu; C Chen; B Sun Journal: J Perinatol Date: 2016-07-21 Impact factor: 2.521
Authors: W E Truog; L D Nelin; A Das; D E Kendrick; E F Bell; W A Carlo; R D Higgins; A R Laptook; P J Sanchez; S Shankaran; B J Stoll; K P Van Meurs; M C Walsh Journal: J Perinatol Date: 2014-06-05 Impact factor: 2.521
Authors: S C Handley; R H Steinhorn; A O Hopper; B Govindaswami; D R Bhatt; K P Van Meurs; R L Ariagno; J B Gould; H C Lee Journal: J Perinatol Date: 2016-03-31 Impact factor: 2.521